Fig. 2
Suppression of LINC00461 by MPT0B291 inhibits tumor growth and improves survival of mice-bearing intracranial GBM. A Growth curves show average tumor volumes from 1 × 106 Pt#3 cells and 1 × 106 U87MG cells injected into the dorsal flanks of NOD/SCID mice. MPT0B291 was administered after the tumor volume reached a size of 10–20 mm3 every other day (n ≥ 5 per group). Two-way ANOVA. B Average final tumor weights of control and MPT0B291-treated xenografts (n ≥ 5 per group). Unpaired Student’s t-test. C Images of control and MPT0B291-treated xenografts at the end of the experiment (n ≥ 5 per group). D ISH and FISH detected the expression of LINC00461. Serial sections of control and MPT0B291-treated xenografts were hybridized with either a LINC00461 probe or a scramble probe in ISH and FISH, and cell nuclei were stained with nuclear fast red and DAPI, respectively, in ISH (left 4 panels) and FISH (right 4 panels) staining. Scale bars indicate 10 μm (inset of ISH), 100 μm (ISH), 13.07 μm (inset of FISH), and 26.22 μm (FISH). E Relative percentages of LINC00461 expression in the cells of control and MPT0B291-treated xenografts were measured by fluorescent intensity. F The Kaplan–Meier plot represents the survival time of BALB/c nude mice-bearing orthotopically implanted 5 × 105 Pt#3 cells. MPT0B291 (10 mg/kg) was administered 5 d after cell implantation every other day (n = 6 per group). Log-rank test. G The expression levels of LINC00461 in Pt#3 cells stably expressing either LINC00461 or empty vector control (pcDNA3.1). Unpaired Student’s t-test. H The Kaplan–Meier plot represents the survival time of BALB/c nude mice-bearing orthotopically implanted 5 × 105 Pt#3 cells stably expressing either LINC00461 or empty vector control (pcDNA3.1) (n = 8–9 per group). Log-rank test. The results are shown as mean ± SEM for triplicate samples in each group